Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.

European journal of clinical pharmacology - 1 Oct 2011

Tanii Hiromi, Shitara Yoshihisa, Horie Toshiharu

Abstract excerpt

PURPOSE: Letrozole is an orally active aromatase inhibitor for the treatment of breast cancer. The objectives of this study were to examine the pharmacokinetic profile of letrozole in Japanese subjects and to identify factors that influence variability in the pharmacokinetics of letrozole using population pharmacokinetic (PPK) analysis. METHODS: Twenty-five healthy postmenopausal Japanese women were enrolled in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to Bilirubin
Share to Creatinine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2A6

Share to Estrone

Share to Nitriles

Share to Postmenopause

Share to Triazoles

Source

Identifiers

PMID: 21494765
DOI: 10.1007/s00228-011-1042-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.PMID 21494765Read ↗

The pharmacokinetics of letrozole: association with key body mass metrics.Semantic proximity Read ↗

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.Semantic proximity Read ↗

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.Semantic proximity Read ↗

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.Semantic proximity Read ↗

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerSemantic proximity Read ↗

The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.Semantic proximity Read ↗

Anastrozole.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.